| Budget Amount *help |
¥20,150,000 (Direct Cost: ¥15,500,000、Indirect Cost: ¥4,650,000)
Fiscal Year 2018: ¥5,460,000 (Direct Cost: ¥4,200,000、Indirect Cost: ¥1,260,000)
Fiscal Year 2017: ¥6,890,000 (Direct Cost: ¥5,300,000、Indirect Cost: ¥1,590,000)
Fiscal Year 2016: ¥7,800,000 (Direct Cost: ¥6,000,000、Indirect Cost: ¥1,800,000)
|
|---|
| Outline of Final Research Achievements |
Although retinal degeneration in retinitis pigmentosa (RP) is initiated by genetic mutations, recent evidence indicate that chronic inflammation modulates the disease progression of RP. Microglia and monocyte/macrophage are key players in neuroinflammation; however, their phenotype changes and functions in RP are still elusive. In the present study, we showed that monocyte/macrophage promoted photoreceptor cell death, while microglia exhibited protective effect in rd10 mice, a model of RP. Novel nanoparticles (NP) efficiently transduced the encapsulated contents into the monocyte/macrophage, and may serve as a potential anti-inflammatory therapy for RP.
|
